Citizens JMP downgraded Allogene Therapeutics (ALLO) to Market Perform from Outperform without a price target post the Q1 report. The firm cites a lack of near-term milestones and longer than expected ALPHA3 development timelines for the downgrade. The firm removed the ALLO-501A revenues from its model, which was the lead program driving its valuation methodology for the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics Advances Clinical Trials and Extends Cash Runway
- Allogene Therapeutics reports Q1 EPS (28c), consensus (29c)
- ALLO Upcoming Earnings Report: What to Expect?
- Allogene Therapeutics to present updated ALLO-316 results at ASCO meeting
- Allogene Therapeutics granted three Fast Track Designations for ALLO-329